GlassScriptPhysician profile
Aimee Charles
NPI 1841936952
$8,792.76
in general payments reported to CMS, 2019-2025
27 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $469 · 2023: $2,582 · 2024: $3,364 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,227 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,226.68 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,669.62 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $871.85 | 2022-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Supernus Pharmaceuticals, INC. | $862.68 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $743.92 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $675.74 | 2022-2025 | Caplyta |
| Tris Pharma INC | $579.42 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $445.44 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $415.34 | 2022-2025 | Trintellix |
| Axsome Therapeutics, INC. | $372.45 | 2023-2025 | Auvelity, Sunosi |
| Idorsia Pharmaceuticals US INC | $302.38 | 2022-2024 | Quviviq |
| Lundbeck LLC | $208.05 | 2023-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $196.03 | 2024 | |
| Vanda Pharmaceuticals INC. | $173.89 | 2025 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $166.30 | 2023-2025 | Adzenys Xr-Odt, Exxua |
| Janssen Pharmaceuticals, INC | $156.92 | 2023-2025 | Spravato, Invega Sustenna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $153.99 | 2022-2024 | Loreev Xr, Gralise |
| Novo Nordisk INC | $146.30 | 2023-2024 | Wegovy |
| Bausch Health US, LLC | $140.37 | 2022-2024 | Wellbutrin, Aplenzin |
| Sunovion Pharmaceuticals INC. | $99.72 | 2022 | |
| Collegium Pharmaceutical, INC. | $97.79 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $88.47 | 2024-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $70.68 | 2023 | Nuplazid |
| Noven Therapeutics, LLC | $52.72 | 2023-2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $51.08 | 2024-2025 | Cobenfy |
| Noven Pharmaceuticals, INC. | $18.63 | 2024 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $17.00 | 2025 | Relexxii |
| Lilly USA, LLC | $15.98 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.